Buy Rating for Mediwound Backed by Strong Revenue Growth and Solid Pipeline Prospects
MediWound Analyst Ratings
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
HC Wainwright & Co. : The MediWound (MDWD.US) rating was reaffirmed, adjusted from buy to buy, and the target price was adjusted from $28.00 to $28.00.
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Mediwound (MDWD)
Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)
MediWound Analyst Ratings
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
Mediwound's EscharEx: A Buy Rating on Potential Market Disruption and Superior Clinical Performance
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $28
MediWound Analyst Ratings
Mediwound Poised for Growth: Buy Rating Affirmed Amidst FDA Progress, Revenue Forecasts, and Expansion Potential
Mediwound's Promising Outlook: Buy Rating Justified by Q3 Results and Expanding Market Opportunities
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $26 Price Target
MediWound Analyst Ratings
Maxim Group Sticks to Their Buy Rating for Mediwound (MDWD)
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $26
MediWound Analyst Ratings
Mediwound (MDWD) Receives a Buy From H.C. Wainwright
Maxim Group Sticks to Its Buy Rating for Mediwound (MDWD)
No Data